Zakrzewski Joseph S's Form 4/A amendment
AmendedCyteir Therapeutics, Inc. (CYT) · filed Dec 8, 2022
- Accession no.
- 0001209191-22-060431
- Filed
- Dec 8, 2022
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 8, 2022
This filing lists no transactions. It carries over 1 transaction from the original filing that it did not restate. Open-market purchases total $27.6K.
This amendment restates part of 0001209191-22-060377 (filed Dec 8, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zakrzewski Joseph SCIK 0001331852 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001209191-22-060377 (filed Dec 8, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 7, 2022 | Common Stock | PPurchaseAcquired | +21,202 | $1.30F1 | +$27,562.6 | 154,618 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $1.28 to $1.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The original Form 4 filed on December 8, 2022 reported securities in column 5 of Table I as indirectly beneficially owned by the Reporting Person through Z Investments, LLC, but these securities were previously transferred to the Reporting Person and should have been reported as directly beneficially owned by the Reporting Person.
- F2
27,551 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
- F3
Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
Remarks
As noted in Footnote 1, this Form 4/A amends the Form 4 filed on December 8, 2022 for this Reporting Person.